Winslow Evans & Crocker’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Winslow Evans & Crocker’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-50	Closed	-$2.28K	–	1213
2017 Q2	$2.28K	Sell	50 -216	-81%	-$9.32K	﹤0.01%	1171
2017 Q1	$11.2K	Sell	266 -2,164	-89%	-$90.7K	﹤0.01%	864
2016 Q4	$94.3K	Hold	2,430	–	–	0.03%	415
2016 Q3	$102K	Sell	2,430 -76	-3%	-$3.12K	0.03%	404
2016 Q2	$92.7K	Sell	2,506 -525	-17%	-$20.6K	0.03%	398
2016 Q1	$116K	Sell	3,031 -347	-10%	-$13.5K	0.04%	340
2015 Q4	$171K	Sell	3,378 -94	-3%	-$4.64K	0.05%	316
2015 Q3	$159K	Buy	3,472 +18	+0.5%	+$1.01K	0.05%	311
2015 Q2	$201K	Buy	3,454 +408	+13%	+$23.3K	0.06%	306
2015 Q1	$168K	Hold	3,046	–	–	0.05%	331
2014 Q4	$153K	Hold	3,046	–	–	0.04%	329
2014 Q3	$141K	Sell	3,046 -184	-6%	-$8.29K	0.04%	363
2014 Q2	$141K	Hold	3,230	–	–	0.05%	310
2014 Q1	$134K	Hold	3,230	–	–	0.05%	312
2013 Q4	$120K	Buy	+3,230	New	+$116K	0.04%	348

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CAS

Cue Advisory Services Phoenix, Arizona $167M AUM 18.62% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Winslow Evans & Crocker's PBE Position: Q3 2017 in Review

Winslow Evans & Crocker sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2017, closing a stake of 50 shares — an estimated $2.28K sold.

Winslow Evans & Crocker first reported a position in PBE in Q4 2013 and held it in 15 quarters. The position peaked at $201K in Q2 2015. 60 funds tracked by Wall St. Rank hold PBE as of Q3 2017.

Winslow Evans & Crocker reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2017 after selling out during the quarter.
Winslow Evans & Crocker sold 50 Invesco Biotechnology & Genome ETF shares in Q3 2017, an estimated $2.28K.
Winslow Evans & Crocker first reported a position in Invesco Biotechnology & Genome ETF in Q4 2013 and held it in 15 quarters.
Winslow Evans & Crocker's Invesco Biotechnology & Genome ETF position peaked at $201K in Q2 2015.
60 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2017.

Based on Winslow Evans & Crocker's 13F filing for Q3 2017, filed 19 Oct 2017.